xTAG

NextPoint Therapeutics Nominates Third Clinical Program Targeting HHLA2/B7-H7

IN8bio to Lay off Nearly Half of Workforce, Narrow Pipeline Focus on AML Cell Therapy

BioMarin Announces New Strategy, Structure Aimed at Reaching $4B Revenue Goal

Promising 12-Month Data on Atsena's LCA1 Gene Therapy Bolsters Case of Pivotal Trial

In Brief This Week: Obsidian, Skyline, Mainz Biomed, Novartis, Synthekine, Vivet, Abdera

HudsonAlpha Researchers Nab $2.9M NIH Grant to Help Solve Rare Diseases With Long-Read Sequencing